Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPG Block for Post-Stroke Headache
NCT05365880Phase 2Withdrawn
- Sponsor
- University of Utah
- Start
- Mar 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in headache attributed to stroke comparing Liquid Lidocaine with Sham Placebo (2 arms). Primary endpoint: Change in Number of Migraine Headaches at 90 days. Planned start Mar 2022; status: withdrawn.
02
Drugs
lidocaine
03
Conditions
headache attributed to stroke
Beyond the preview
Go deeper on NCT05365880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365880.